EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieÄquivalenzstudie

A Randomized, Double-Blind Crossover Study of Change in Post-Dose Lung Function with Hydrofluoroolefin-1234ze, a Next-Generation Propellant for Metered Dose Inhalers, in Participants with Asthma

Roy A Pleasants iD, Alan S Bell, Mandeep Jassal, John Xu, David Petullo, Ibrahim Raphiou, Magnus Aurivillius, Patrik Bondarov, Mehul Patel

Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2025

DOI: 10.1089/jamp.2024.0061 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2025. Verfasst von Roy A Pleasants und 8 weiteren Autor:innen. Beteiligte Einrichtung: Marsico Lung Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Asthma, Metered Dose Inhalers, Aerosol Propellants, Hydrocarbons, Fluorinated. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pressurized metered dose inhalers (pMDIs) currently contain propellants with relatively high global warming potential (GWP), such as hydrofluoroalkane-134a (HFA-134a). Hyrofluoroolefin-1234ze (HFO-1234ze) is a near-zero GWP propellant in development for use in future pMDIs.

Methods

This Phase IIIb, multicenter, randomized, double-blind, single-dose crossover study aimed to assess post-dose lung function and clinical manifestations of bronchospasm following single doses of HFA-134a and HFO-1234ze via pMDI (four inhalations with no active drugs) in participants with well or partially controlled asthma. The primary endpoint was change from baseline in forced expiratory volume in one second area under the curve from 0 to 15 minutes (FEV1 AUC0-15 minutes) post-dose and was assessed using a linear mixed-effect model. Secondary endpoints included cumulative incidence of bronchospasm events (reduction in FEV1 of >15% from baseline at 5 or 15 minutes post-dose with associated wheezing, shortness of breath, or cough). Safety and tolerability were also assessed.

Results

Among 52 participants randomized to treatment, noninferiority of HFO-1234ze pMDI versus HFA-134a was established for change from baseline in FEV1 AUC0-15 minutes post-dose between treatments (least squares mean [LSM]; 95% confidence intervals [CI] change: HFO-1234ze pMDI, -0.014 [-0.033, 0.006] L; HFA-134a, -0.004 [-0.024, 0.015] L; LSM [95% CI] difference: -0.009 [-0.037, 0.018; p = 0.492]). No bronchospasm events were reported. Two patients (3.8%) in each group experienced ≥1 adverse event (AE). No serious AEs, AEs of special interest, or AEs leading to discontinuation were reported.

Conclusions

HFO-1234ze pMDI was well tolerated in participants with well or partially controlled asthma. As with HFA-134a pMDI, no significant effects on lung function or bronchospasm events were observed. As HFO-1234ze pMDI has a near-zero GWP, it represents a compelling, environmentally conscious alternative propellant for use in pMDI devices for treatment of chronic respiratory disease. Trial Registration: NCT05850494.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaMetered Dose InhalersAerosol PropellantsHydrocarbons, FluorinatedLungHumansDouble-Blind MethodMaleCross-Over StudiesFemaleAdultMiddle AgedForced Expiratory VolumeAdministration, InhalationBronchial SpasmYoung AdultAgedFluorocarbons

Stichwörter der Autor:innen

asthmabronchospasmhydrofluoroolefin-1234zemetered dose inhaler

Substanzen

Aerosol PropellantsHydrocarbons, FluorinatedapafluraneFluorocarbons

Autor:innen und Institutionen

  • Marsico Lung Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Respiratory and Immunology Biometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Durham, North Carolina, USA.

ORCID-Profile: Roy A Pleasants

Zitieren

APA

Pleasants, R. A., Bell, A. S., Jassal, M., Xu, J., Petullo, D., Raphiou, I., Aurivillius, M., Bondarov, P., & Patel, M. (2025). A Randomized, Double-Blind Crossover Study of Change in Post-Dose Lung Function with Hydrofluoroolefin-1234ze, a Next-Generation Propellant for Metered Dose Inhalers, in Participants with Asthma. Journal of Aerosol Medicine and Pulmonary Drug Delivery. https://doi.org/10.1089/jamp.2024.0061

Vancouver

Pleasants RA, Bell AS, Jassal M, Xu J, Petullo D, Raphiou I, et al. A Randomized, Double-Blind Crossover Study of Change in Post-Dose Lung Function with Hydrofluoroolefin-1234ze, a Next-Generation Propellant for Metered Dose Inhalers, in Participants with Asthma. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2025. doi:10.1089/jamp.2024.0061

BibTeX
@article{Pleasants2025,
  author = {Pleasants, Roy A and Bell, Alan S and Jassal, Mandeep and Xu, John and Petullo, David and Raphiou, Ibrahim and Aurivillius, Magnus and Bondarov, Patrik and Patel, Mehul},
  title = {A Randomized, Double-Blind Crossover Study of Change in Post-Dose Lung Function with Hydrofluoroolefin-1234ze, a Next-Generation Propellant for Metered Dose Inhalers, in Participants with Asthma},
  journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
  year = {2025},
  doi = {10.1089/jamp.2024.0061}
}
Kostenlos starten →